Active — Not RecruitingNot Applicable

Longitudinal FolloW-up of Antimicrobial Resistance From Perinatal Acquisition (LWAPA): A SHARE Study ASSESSING AND PREVENTING Antimicrobial Resistance in the Perinatal Period

Botswana1,000 participantsStarted 2024-02-15

Plain-language summary

In 2022, in collaboration between the Botswana Ministry of Health (MOH), the U.S. Centers for Disease Control \& Prevention, and the Botswana-UPenn Partnership (BUP), a program was launched called, "Surveillance of Healthcare-associated infections \& Antimicrobial Resistance", or "SHARE". The aims of SHARE are to 1) enhance laboratory capacity to detect emerging AMR patterns; 2) strengthen hospital epidemiology programs, leveraging data to prevent, detect, and contain emerging AMR threats; 3) deploy study teams to answer critical public health surveillance questions, and 4) to build a national network of hospital infection prevention and control (IPC) resources to prevent, detect, and contain emerging infectious disease threats.

Who can participate

Age range36 Weeks

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Pre-partum mothers will be eligible for recruitment if they have been admitted to the pre-partum ward (2F) at PMH. This includes mothers with: * Pre-term labor (24-36 weeks gestation) * Pre-eclampsia * Post-dates (\>41 weeks gestation)- Exclusion Criteria: Mothers/babies who have been admitted for more than 96 hours will be excluded

What they're measuring

Longitudinal FolloW-up of Antimicrobial Resistance from Perinatal Acquisition

Timeframe: 12 months

Trial details

NCT IDNCT06617260

SponsorUniversity of Pennsylvania

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-02-28

View on ClinicalTrials.gov More Drug Resistance, Microbial trials